



Kidney Health Care Program Notice: Expanded Medicare Coverage of Immunosuppressive Drugs for Kidney Transplant Patients

This is an important notice for all Kidney Health Care (KHC) clients who have received, or will receive, a kidney transplant.

Effective January 1, 2023, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act will provide lifetime Medicare coverage of immunosuppressant drugs (ISDs) for kidney transplant recipients who are eligible for Medicare. Medicare Part B – Immunosuppressive Drug (Medicare Part B-ID), provides coverage for ISDs beyond the 36-month post-transplant period. The enrollment period for all eligible clients began October 1, 2022. For more information on the Medicare Part B-ID benefit visit the [Medicare End-Stage Renal Disease \(ESRD\) website](#).

With this expanded Medicare Part B-ID benefit, all KHC clients who were enrolled in Medicare at the time of transplant and who received a transplant from a Medicare-approved facility, will qualify for lifetime Medicare coverage of ISDs, regardless of age.

In addition, KHC clients who have received, or will receive, a kidney transplant, and do not have other insurance for drug coverage, will be eligible to enroll in Medicare Part B-ID solely for ISD coverage. KHC will continue to be the secondary payer for any copays and deductibles for all clients enrolled in Medicare Part B and Part B-ID.

KHC encourages all eligible clients to enroll in Medicare Part B-ID to maintain coverage for ISDs beyond the 36-month post-transplant period. At this time, the Standard KHC Drug Benefit will continue to be available for eligible KHC clients. For additional information on KHC Drug Benefits, please see the [Kidney Health Care Client Handbook](#) on our [KHC client website](#).

For information on enrollment for this Medicare benefit, visit the [Medicare ESRD website](#) or call 877-465-0355 (TTY 800-325-0778).